1
|
Tantry SJ, Markad SD, Shinde V, Bhat J, Balakrishnan G, Gupta AK, Ambady A, Raichurkar A, Kedari C, Sharma S, Mudugal NV, Narayan A, Naveen Kumar CN, Nanduri R, Bharath S, Reddy J, Panduga V, Prabhakar KR, Kandaswamy K, Saralaya R, Kaur P, Dinesh N, Guptha S, Rich K, Murray D, Plant H, Preston M, Ashton H, Plant D, Walsh J, Alcock P, Naylor K, Collier M, Whiteaker J, McLaughlin RE, Mallya M, Panda M, Rudrapatna S, Ramachandran V, Shandil R, Sambandamurthy VK, Mdluli K, Cooper CB, Rubin H, Yano T, Iyer P, Narayanan S, Kavanagh S, Mukherjee K, Balasubramanian V, Hosagrahara VP, Solapure S, Ravishankar S, Hameed P S. Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis. J Med Chem 2017; 60:1379-1399. [PMID: 28075132 DOI: 10.1021/acs.jmedchem.6b01358] [Citation(s) in RCA: 81] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The approval of bedaquiline to treat tuberculosis has validated adenosine triphosphate (ATP) synthase as an attractive target to kill Mycobacterium tuberculosis (Mtb). Herein, we report the discovery of two diverse lead series imidazo[1,2-a]pyridine ethers (IPE) and squaramides (SQA) as inhibitors of mycobacterial ATP synthesis. Through medicinal chemistry exploration, we established a robust structure-activity relationship of these two scaffolds, resulting in nanomolar potencies in an ATP synthesis inhibition assay. A biochemical deconvolution cascade suggested cytochrome c oxidase as the potential target of IPE class of molecules, whereas characterization of spontaneous resistant mutants of SQAs unambiguously identified ATP synthase as its molecular target. Absence of cross resistance against bedaquiline resistant mutants suggested a different binding site for SQAs on ATP synthase. Furthermore, SQAs were found to be noncytotoxic and demonstrated efficacy in a mouse model of tuberculosis infection.
Collapse
Affiliation(s)
- Subramanyam J Tantry
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Shankar D Markad
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Vikas Shinde
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Jyothi Bhat
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Gayathri Balakrishnan
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Amit K Gupta
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Anisha Ambady
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Anandkumar Raichurkar
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Chaitanyakumar Kedari
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Sreevalli Sharma
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Naina V Mudugal
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Ashwini Narayan
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - C N Naveen Kumar
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Robert Nanduri
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Sowmya Bharath
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Jitendar Reddy
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Vijender Panduga
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - K R Prabhakar
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Karthikeyan Kandaswamy
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Ramanatha Saralaya
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Parvinder Kaur
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Neela Dinesh
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Supreeth Guptha
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Kirsty Rich
- AstraZeneca , Alderley Park, Mereside, Macclesfield, Cheshire U.K. SK10 4TG
| | - David Murray
- AstraZeneca , Alderley Park, Mereside, Macclesfield, Cheshire U.K. SK10 4TG
| | - Helen Plant
- AstraZeneca , Alderley Park, Mereside, Macclesfield, Cheshire U.K. SK10 4TG
| | - Marian Preston
- AstraZeneca , Alderley Park, Mereside, Macclesfield, Cheshire U.K. SK10 4TG
| | - Helen Ashton
- AstraZeneca , Alderley Park, Mereside, Macclesfield, Cheshire U.K. SK10 4TG
| | - Darren Plant
- AstraZeneca , Alderley Park, Mereside, Macclesfield, Cheshire U.K. SK10 4TG
| | - Jarrod Walsh
- AstraZeneca , Alderley Park, Mereside, Macclesfield, Cheshire U.K. SK10 4TG
| | - Peter Alcock
- AstraZeneca , Alderley Park, Mereside, Macclesfield, Cheshire U.K. SK10 4TG
| | - Kathryn Naylor
- AstraZeneca , Alderley Park, Mereside, Macclesfield, Cheshire U.K. SK10 4TG
| | - Matthew Collier
- AstraZeneca , Alderley Park, Mereside, Macclesfield, Cheshire U.K. SK10 4TG
| | - James Whiteaker
- Infection Innovative Medicines, AstraZeneca , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
| | - Robert E McLaughlin
- Infection Innovative Medicines, AstraZeneca , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
| | - Meenakshi Mallya
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Manoranjan Panda
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Suresh Rudrapatna
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Vasanthi Ramachandran
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Radha Shandil
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Vasan K Sambandamurthy
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Khisi Mdluli
- Global Alliance for TB Drug Development , 40 Wall Street, 24th Floor, New York, New York 10005, United States
| | - Christopher B Cooper
- Global Alliance for TB Drug Development , 40 Wall Street, 24th Floor, New York, New York 10005, United States
| | - Harvey Rubin
- University of Pennsylvania , 111 Clinical Research Building, 415 Curie Boulevard, Philadelphia Pennsylvania 19104, United States
| | - Takahiro Yano
- University of Pennsylvania , 111 Clinical Research Building, 415 Curie Boulevard, Philadelphia Pennsylvania 19104, United States
| | - Pravin Iyer
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Shridhar Narayanan
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Stefan Kavanagh
- AstraZeneca , Alderley Park, Mereside, Macclesfield, Cheshire U.K. SK10 4TG
| | - Kakoli Mukherjee
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - V Balasubramanian
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Vinayak P Hosagrahara
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Suresh Solapure
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Sudha Ravishankar
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| | - Shahul Hameed P
- Innovative Medicines, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India
| |
Collapse
|
3
|
Landge S, Mullick AB, Nagalapur K, Neres J, Subbulakshmi V, Murugan K, Ghosh A, Sadler C, Fellows MD, Humnabadkar V, Mahadevaswamy J, Vachaspati P, Sharma S, Kaur P, Mallya M, Rudrapatna S, Awasthy D, Sambandamurthy VK, Pojer F, Cole ST, Balganesh TS, Ugarkar BG, Balasubramanian V, Bandodkar BS, Panda M, Ramachandran V. Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase. Bioorg Med Chem 2015; 23:7694-710. [PMID: 26643218 DOI: 10.1016/j.bmc.2015.11.017] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Revised: 11/11/2015] [Accepted: 11/16/2015] [Indexed: 11/18/2022]
Abstract
We report the discovery of benzothiazoles, a novel anti-mycobacterial series, identified from a whole cell based screening campaign. Benzothiazoles exert their bactericidal activity against Mycobacterium tuberculosis (Mtb) through potent inhibition of decaprenylphosphoryl-β-d-ribose 2'-oxidase (DprE1), the key enzyme involved in arabinogalactan synthesis. Specific target linkage and mode of binding were established using co-crystallization and protein mass spectrometry studies. Most importantly, the current study provides insights on the utilization of systematic medicinal chemistry approaches to mitigate safety liabilities while improving potency during progression from an initial genotoxic hit, the benzothiazole N-oxides (BTOs) to the lead-like AMES negative, crowded benzothiazoles (cBTs). These findings offer opportunities for development of safe clinical candidates against tuberculosis. The design strategy adopted could find potential application in discovery of safe drugs in other therapy areas too.
Collapse
Affiliation(s)
- Sudhir Landge
- iMed Infection, AstraZeneca India Pvt Ltd, Bangalore, India
| | | | | | - João Neres
- École Polytechnique Fédérale de Lausanne, Global Health Institute, Switzerland
| | | | - Kannan Murugan
- iMed Infection, AstraZeneca India Pvt Ltd, Bangalore, India
| | - Anirban Ghosh
- iMed Infection, AstraZeneca India Pvt Ltd, Bangalore, India
| | - Claire Sadler
- Global Safety Assessment, AstraZeneca, Alderley Park, Mereside, UK
| | - Mick D Fellows
- Global Safety Assessment, AstraZeneca, Alderley Park, Mereside, UK
| | | | | | | | | | - Parvinder Kaur
- iMed Infection, AstraZeneca India Pvt Ltd, Bangalore, India
| | | | | | - Disha Awasthy
- iMed Infection, AstraZeneca India Pvt Ltd, Bangalore, India
| | | | - Florence Pojer
- École Polytechnique Fédérale de Lausanne, Global Health Institute, Switzerland
| | - Stewart T Cole
- École Polytechnique Fédérale de Lausanne, Global Health Institute, Switzerland
| | | | | | | | | | | | | |
Collapse
|
4
|
Ravishankar S, Ambady A, Awasthy D, Mudugal NV, Menasinakai S, Jatheendranath S, Guptha S, Sharma S, Balakrishnan G, Nandishaiah R, Ramachandran V, Eyermann CJ, Reck F, Rudrapatna S, Sambandamurthy VK, Sharma UK. Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target. Tuberculosis (Edinb) 2015; 95:589-98. [PMID: 26073894 DOI: 10.1016/j.tube.2015.05.004] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Revised: 04/30/2015] [Accepted: 05/13/2015] [Indexed: 12/21/2022]
Abstract
DNA topoisomerases perform the essential function of maintaining DNA topology in prokaryotes. DNA gyrase, an essential enzyme that introduces negative supercoils, is a clinically validated target. However, topoisomerase I (Topo I), an enzyme responsible for DNA relaxation has received less attention as an antibacterial target, probably due to the ambiguity over its essentiality in many organisms. The Mycobacterium tuberculosis genome harbors a single topA gene with no obvious redundancy in its function suggesting an essential role. The topA gene could be inactivated only in the presence of a complementing copy of the gene in M. tuberculosis. Furthermore, down-regulation of topA in a genetically engineered strain of M. tuberculosis resulted in loss of bacterial viability which correlated with a concomitant depletion of intracellular Topo I levels. The topA knockdown strain of M. tuberculosis failed to establish infection in a murine model of TB and was cleared from lungs in two months post infection. Phenotypic screening of a Topo I overexpression strain led to the identification of an inhibitor, thereby providing chemical validation of this target. Thus, our work confirms the attractiveness of Topo I as an anti-mycobacterial target.
Collapse
Affiliation(s)
- Sudha Ravishankar
- AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India.
| | - Anisha Ambady
- AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India
| | - Disha Awasthy
- AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India
| | | | | | | | - Supreeth Guptha
- AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India
| | - Sreevalli Sharma
- AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India
| | | | - Radha Nandishaiah
- AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India
| | | | - Charles J Eyermann
- AstraZeneca Infection, Innovative Medicines, 35 Gatehouse Drive, Waltham, MA 02451, United States
| | - Folkert Reck
- AstraZeneca Infection, Innovative Medicines, 35 Gatehouse Drive, Waltham, MA 02451, United States
| | - Suresh Rudrapatna
- AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India
| | | | - Umender K Sharma
- AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India
| |
Collapse
|
5
|
Naik M, Humnabadkar V, Tantry SJ, Panda M, Narayan A, Guptha S, Panduga V, Manjrekar P, Jena LK, Koushik K, Shanbhag G, Jatheendranath S, Manjunatha MR, Gorai G, Bathula C, Rudrapatna S, Achar V, Sharma S, Ambady A, Hegde N, Mahadevaswamy J, Kaur P, Sambandamurthy VK, Awasthy D, Narayan C, Ravishankar S, Madhavapeddi P, Reddy J, Prabhakar KR, Saralaya R, Chatterji M, Whiteaker J, McLaughlin B, Chiarelli LR, Riccardi G, Pasca MR, Binda C, Neres J, Dhar N, Signorino-Gelo F, McKinney JD, Ramachandran V, Shandil R, Tommasi R, Iyer PS, Narayanan S, Hosagrahara V, Kavanagh S, Dinesh N, Ghorpade SR. 4-Aminoquinolone Piperidine Amides: Noncovalent Inhibitors of DprE1 with Long Residence Time and Potent Antimycobacterial Activity. J Med Chem 2014; 57:5419-34. [DOI: 10.1021/jm5005978] [Citation(s) in RCA: 65] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Laurent R. Chiarelli
- Department
of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, 27100 Pavia, Italy
| | - Giovanna Riccardi
- Department
of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, 27100 Pavia, Italy
| | - Maria Rosalia Pasca
- Department
of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, 27100 Pavia, Italy
| | - Claudia Binda
- Department
of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, 27100 Pavia, Italy
| | - João Neres
- École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
| | - Neeraj Dhar
- École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
| | | | - John D. McKinney
- École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
| | | | | | | | | | | | | | - Stefan Kavanagh
- Safety Assessment, AstraZeneca, Alderley
Park, Macclesfield, Cheshire SK10 2NA, United Kingdom
| | | | | |
Collapse
|